Expression of p53, p21/waf, bcl-2, bax, Rb and Ki67 proteins in colorectal adenocarcinomas

Medical Oncology

Volumn 16, Issue 1, 1999, Pages 23-30

  Kanavaros, P ^a   Stefanaki, K ^a   Valassiadou, K ^a   Vlachonikolis, J ^a   Mavromanolakis, M ^a   Vlychou, M ^a   Kakolyris, S ^a   Gorgoulis, V ^b   Tzardi, M ^a   Georgoulias, V ^a,c  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Apoptosis; Colorectal adenocarcinomas; Immunohistochemistry

Indexed keywords

KI 67 ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADENOCARCINOMA; ARTICLE; CANCER GRADING; CANCER STAGING; CARCINOGENESIS; CLINICAL ARTICLE; COLON MUCOSA; COLORECTAL CARCINOMA; CORRELATION FUNCTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RECTUM MUCOSA;

EID: 6544264907     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02787355     Document Type: Article

References (51)

1. Ilyas M, Tomlinson IPM. Genetic pathways in colorectal cancer. Histopathology 1996; 28: 389-399.
2. Levine A, Momand J, Finlay C. The p53 tumour suppressor gene. Nature 1992; 351: 453-456.
3. Nigro MJ et al. Mutations in p53 gene occur in diverse human tumour types. Nature 1989; 342: 705-708.
4. Chilosi M et al. P21/WFA1 cyclin kinase inhibitor expression in non-Hodgkin's lymphomas. A potential marker of p53 tumor-suppressor gene function. Blood 1996; 88: 4012-4020.
5. Cox LS. Multiple pathways control cell growth and transformation: Overlapping and independent activities of p53 and p21. J Pathol 1997; 183: 134-140.
6. El Deiry WS et al. Waf-1 a potential mediator of p53 tumour suppression. Cell 1993; 75: 817-825.
7. Harper JW, Adami GY, Keyomashi K, Ellege SJ. The p21/cdk interacting protein cip1 is a potent inhibitor of Glcyclin dependent kinase. Cell 1993; 75: 805-816.
8. Xiong Y et al. P21 is universal inhibitor of cyclin kinase. Nature 1993; 366: 701-704.
9. Waga S, Hannon GJ, Beach D, Stilman B. The p21 inhibitor of cyclin-dependent kinase controls DNA replication by interactions with PCNA. Nature 1994; 369: 574-578.
10. Steinman RA et al. Induction of p21 (WAF1/CIP1) during differentiation. Oncogene 1994; 9: 3389-3396.
11. Parker SB et al. P53 independent expression of p21 in muscle and other terminally differentiating cells. Science 1995; 267: 1024-1027.
12. Shiohara M et al. Absence of waf1 mutations in a variety of human malignancies. Blood 1994; 84: 3781-3784.
13. Fredersdorf S, Milne AW, Hall PA, Lu X. Characterization of a panel of novel anti p21 (waf1/cip1) monoclonal antibodies and immunochemical analysis of p21 (waf1/ cip1) expression in normal human tissues. Am J Pathol 1996; 148: 825-835.
14. Miyashita T, Reed J. Tumour suppressor p53 is a direct transcriptional activator of human bax gene. Cell 1995; 80: 293-299.
15. Miyashita T et al. Tumour suppressor p53 is a regulator of bcl-2 and bax in gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-1805.
16. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
17. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy induced apoptosis in a leukemia cell line. Blood 1993; 81: 151-157.
18. Antonsson B et al. Inhibition of Bax channel-forming activity by Bcl-2. Science 1997; 277: 370-372.
19. White E. Life, death and the pursuit of apoptosis. Genes Dev 1996; 10: 1-15.
20. Reed JC. Double identity for proteins of the bcl-2 family. Nature 1997; 387: 773-776.
21. Yin C, Knudson M, Korsmeyer SJ, Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997; 385: 637-640.
22. Krajewski S et al. Immunohistochemical determination of in vivo distribution of bax, a dominant inhibitor of bcl-2. Am J Pathol 1994; 145: 1323-1336.
23. Krajewski S et al. Reduced bax expression of proapoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995; 55: 4471-4478.
24. Lu QL, Abel P, Foster CS, Lalani EN. Bcl-2: Role in epithelial differentiation and oncogenesis. Hum Pathol 1996; 27: 102-110.
25. Krajewska M et al. Immunohistochemical analysis of bcl2, bax, bcl-x and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148: 1567-1576.
26. Shiio Y, Yamamoto T, Yamaguchi N. Negative regulation of Rb expression by the p53 gene product. Proc Natl Acad Sci USA 1992; 89: 5206-5210.
27. Mihara K, Cao X-R, Yen A. Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product. Science 1989; 246: 1300-1303.
28. Goodrich DW et al. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 1991; 67: 239-302.
29. Wiman KG. The retinoblastoma gene: Role in cell cycle control and cell differentiation. FASEB J 1993; 7: 841-845.
30. Harbour JW et al. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 1988; 241: 353-355.
31. Tang A, Varley JM, Chakaraborty S, Murphee AL, Fung Y-KT. Structural rearrangements of the retinoblastoma gene in human breast carcinoma. Science 1988; 242: 263-266.
32. Gope R et al. Increased expression of retinoblastoma gene in human colorectal carcinoma relative to normal colonic mucosa. J Natl Cancer Inst 1990; 82: 310-314.
33. Meling GI et al. Genetic alterations within the retinoblastoma locus in colorectal carcinomas. Relation to DNA ploidy pattern studied by flow cytometric analysis. Br J Cancer 1991; 64: 475-480.
34. Cordon-Cardo C, Richon VM. Expression of the retinoblastoma protein is regulated in normal human tissues. Am J Pathol 1994; 3: 144-153.
35. Kastrinakis WV et al. Increased incidence of p53 mutations is associated with hepatic metastases in colorectal neoplastic progression. Oncogene 1995; 11: 647-652.
36. Polyak K, Hamilton SR, Vogelstein B, Kinzler KW. Early alteration of cell-cycle-regulated gene expression in colorectal neoplasia. Am J Pathol 1996; 149: 381-387.
37. Costa A et al. P53 gene point mutations in relation to p53 nuclear accumulation in colorectal cancers. J Pathol 1995; 176: 45-53.
38. Kaklamanis L et al. Early expression of bcl-2 protein in the adenoma-carcinoma sequence of colorectal neoplasia. J Pathol 1996; 179: 10-14.
39. Bronner MP, Culin C, Reed JC, Furth EE. The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol 1995; 146: 20-26.
40. Pallazo JP et al. The role of p53, p21 and bcl2 in radioresistant colorectal carcinoma. Hum Pathol 1997; 28: 1189-1195.
41. Bosari S, Moneghini L, Graziani D. Bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas and adenocarcinomas. Hum Pathol 1995; 26: 534-540.
42. Langlois NE, Lamb J, Eremin O, Hays SD. Apoptosis in colorectal carcinoma occurring in patients aged 45 years and under: relationship to prognosis, mitosos and immunohistochemical demonstration of p53, c-myc and bcl2 protein products. J Pathol 1997; 182: 392-397.
43. El Deiry WS et al. Topological control of p21 (waf1/cip1) expression in normal and neoplastic tissues. Cancer Res 1995; 55: 2910-2919.
44. Doglioni C et al. P21/WAF1/CIP1 expression in normal mucosa, adenomas and adenocarcinomas of the colon: its relationship with differentiation. J Pathol 1996; 179: 248-253.
45. Gope R, Gope ML. Abundance and state of phosphorylation of the retinoblastoma susceptibility gene product in human colon cancer. Mol Cell Biochem 1992; 110: 123-133.
46. Yamamoto H et al. Coexpression of cdk2/cdc2 and retinoblastoma gene products in colorectal cancer. Br J Cancer 1995; 71: 1231-1236.
47. Leahy DI et al. Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis. J Pathol 1996; 180: 364-370.
48. Mueller J et al. Expression of bcl-2 and p53 in de novo and ex-adenoma colon carcinoma. A comparative immunohistochemical study. J Pathol 1996; 180: 259-265.
49. Rampino N et al. Somatic frameshift mutations in the bax gene in colon cancers of the microsatellite mutator phenotype. Science 1997; 275: 967-969.
50. Stefanaki K et al. Immunohistochemical expression of bcl-2, p53. mdm-2 and p21/waf1 proteins in thymomas. Histopathology 1997; 30: 549-555.
51. Martinez JC et al. Retinoblastoma (Rb) gene product expression in lymphomas. Correlation with Ki67 growth fraction. J Pathol 1993; 169: 405-451.